Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy

Author(s): Sander W. Tas, Philip H.J. Remans, Kris A. Reedquist and Paul P. Tak

Volume 11, Issue 5, 2005

Page: [581 - 611] Pages: 31

DOI: 10.2174/1381612053381918

Price: $65

Abstract

Many chronic inflammatory diseases are associated with deregulated intracellular signal transduction pathways. Resultant pathogenic interactions between immune and stromal cells lead to changes in cell activation, proliferation, migratory capacity, and cell survival that all contribute to inflammation. Increasing efforts are now being made in the design of novel therapeutic compounds to interfere with signaling pathways in inflammatory diseases like rheumatoid arthritis (RA). In this review we will outline the major signal transduction pathways involved in the pathogenesis of RA. We will assess advances in targeting a number of key intracellular pathways, including nuclear factor-κB (NF-κB), mitogen-associated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K) / Akt, signal transducers and activators of transcription (STATs), and reactive oxygen species (ROS) production. Finally, we will discuss recently identified lead molecules and the progress of selected compounds towards becoming new drugs for the treatment of inflammatory diseases.

Keywords: inflammatory disease, rheumatoid arthritis, signal transduction, nuclear factor, mitogen-activated protein kinase, reactive oxygen species, novel therapies


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy